Class information for:
Level 1: PEMETREXED//MULTITARGETED ANTIFOLATE//NONSQUAMOUS

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
8141 1215 36.6 79%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 2)


ID, lev.
above		 Publications Label for level above
823 11253 NON SMALL CELL LUNG CANCER//XRCC1//GEFITINIB

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 PEMETREXED Author keyword 147 39% 25% 301
2 MULTITARGETED ANTIFOLATE Author keyword 23 76% 1% 16
3 NONSQUAMOUS Author keyword 15 68% 1% 13
4 LY231514 Author keyword 15 73% 1% 11
5 PEMETREXED DISODIUM Author keyword 15 73% 1% 11
6 NON SQUAMOUS NON SMALL CELL LUNG CANCER Author keyword 11 65% 1% 11
7 NONSQUAMOUS NON SMALL CELL LUNG CANCER Author keyword 11 100% 0% 6
8 NONSQUAMOUS HISTOLOGY Author keyword 8 100% 0% 5
9 ALIMTA Author keyword 8 45% 1% 13
10 BIBF 1120 Author keyword 6 44% 1% 11

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class		 LCSH search Wikipedia search
1 PEMETREXED 147 39% 25% 301 Search PEMETREXED Search PEMETREXED
2 MULTITARGETED ANTIFOLATE 23 76% 1% 16 Search MULTITARGETED+ANTIFOLATE Search MULTITARGETED+ANTIFOLATE
3 NONSQUAMOUS 15 68% 1% 13 Search NONSQUAMOUS Search NONSQUAMOUS
4 LY231514 15 73% 1% 11 Search LY231514 Search LY231514
5 PEMETREXED DISODIUM 15 73% 1% 11 Search PEMETREXED+DISODIUM Search PEMETREXED+DISODIUM
6 NON SQUAMOUS NON SMALL CELL LUNG CANCER 11 65% 1% 11 Search NON+SQUAMOUS+NON+SMALL+CELL+LUNG+CANCER Search NON+SQUAMOUS+NON+SMALL+CELL+LUNG+CANCER
7 NONSQUAMOUS NON SMALL CELL LUNG CANCER 11 100% 0% 6 Search NONSQUAMOUS+NON+SMALL+CELL+LUNG+CANCER Search NONSQUAMOUS+NON+SMALL+CELL+LUNG+CANCER
8 NONSQUAMOUS HISTOLOGY 8 100% 0% 5 Search NONSQUAMOUS+HISTOLOGY Search NONSQUAMOUS+HISTOLOGY
9 ALIMTA 8 45% 1% 13 Search ALIMTA Search ALIMTA
10 BIBF 1120 6 44% 1% 11 Search BIBF+1120 Search BIBF+1120

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 LY231514 72 59% 7% 81
2 MULTITARGETED ANTIFOLATE 71 54% 7% 91
3 MULTITARGETED ANTIFOLATE LY231514 71 72% 5% 55
4 AVAIL 38 89% 1% 17
5 CISPLATIN PLUS GEMCITABINE 35 32% 8% 92
6 MTA LY231514 35 81% 2% 21
7 TRIPLE ANGIOKINASE INHIBITOR 28 50% 3% 40
8 LY231514 MTA 21 85% 1% 11
9 VANDETANIB PLUS DOCETAXEL 15 59% 1% 17
10 DISODIUM 14 26% 4% 48

Journals

Reviews


Title Publ. year Cit. Active
references		 % act. ref.
to same field
Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer 2013 52 46 39%
The Use of Bevacizumab in Non-Small Cell Lung Cancer: An Update 2014 13 35 69%
Antiangiogenic Agents in Combination with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer 2011 39 72 58%
Novel angiogenesis inhibitors in nonsmall cell lung cancer 2015 1 33 58%
Maintenance Chemotherapy for Advanced Non-Small-Cell Lung Cancer: New Life for an Old Idea 2013 19 72 38%
Antiangiogenic agents in the management of non-small cell lung cancer Where do we stand now and where are we headed? 2012 16 63 62%
Targeting VEGF in lung cancer 2012 16 53 60%
Effectiveness and Safety of Pemetrexed Versus Docetaxel as a Treatment for Advanced Non-small Cell Lung Cancer: a Systematic Review and Meta-analysis 2014 2 14 71%
Expression of thymidylate synthase predicts clinical outcomes of pemetrexed-containing chemotherapy for non-small-cell lung cancer: a systemic review and meta-analysis 2013 8 38 50%
Addition of Bevacizumab to Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis 2011 28 25 44%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 ONCOL EMERGING MARKETS 4 75% 0.2% 3
2 THORAC ONCOL UNIT 3 16% 1.6% 19
3 SEVERANCE INT HLTH CARE 3 100% 0.2% 3
4 ONCOL PULM UNIT 1 2 38% 0.4% 5
5 THORAC HEAD NECK MED ONCOL CANC BIOL 2 67% 0.2% 2
6 MULTIDISCIPLINARY THORAC ONCOL PROGRAM 2 14% 1.2% 14
7 REG LUNG DIS 2 50% 0.2% 3
8 SURG INTERDISCIPLINARY THORAC ONCOL 2 50% 0.2% 3
9 TLRC H 2 50% 0.2% 3
10 THORAC ONCOL UNIT 1 2 40% 0.3% 4

Related classes at same level (level 1)


Rank Relatedness score Related classes
1 0.0000235424 VINORELBINE//GEMCITABINE//ADVANCED NON SMALL CELL LUNG CANCER
2 0.0000207376 GEFITINIB//ERLOTINIB//EGFR MUTATION
3 0.0000137480 TSU 68//APATINIB//MUCOCUTANEOUS TOXICITIES
4 0.0000100426 ERCC1//RRM1//MED OVARIAN CANC SECT
5 0.0000095674 OREGOVOMAB//AFLIBERCEPT//GI PERFORATION
6 0.0000093049 SUNITINIB//METASTATIC RENAL CELL CARCINOMA//CARCINOMA RENAL CELL
7 0.0000077723 PLASMA VEGF//MANCHESTER RENAL GRP//PLASMA VASCULAR ENDOTHELIAL GROWTH FACTOR
8 0.0000067246 OSI 420//OSI 774//CAKI 1 RENAL CELL CARCINOMA
9 0.0000064826 REDUCED FOLATE CARRIER//FOLYLPOLYGLUTAMATE SYNTHETASE//HEREDITARY FOLATE MALABSORPTION
10 0.0000064145 DIARYLAMIDE//VEGFR 2 INHIBITOR//KDR KINASE